ACB
Aurora Cannabis, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.96
−0.75%Oct 16, 2026, 17:54 UTC
AURORA CANNABIS INC is evaluating strategic alternatives in response to Curaleaf Holdings, Inc.'s hostile takeover bid, including a potential third-party transaction or remaining independent, to maximize shareholder value.
Source:Oct 14, 2026, 21:03 UTC
Curaleaf Holdings, Inc. made a revised bid for AURORA CANNABIS INC.
Source:Oct 8, 2026, 11:05 UTC
AURORA CANNABIS INC completed a major expansion of its EU-GMP manufacturing facility in Germany, more than doubling expected annual flower output.
Source:Oct 5, 2026, 12:15 UTC
Curaleaf enhanced its offer to acquire Aurora Cannabis.
Source:Sep 2, 2026, 17:26 UTC
Aurora Cannabis's board rejected an acquisition offer from Curaleaf.
Aug 19, 2026, 18:00 UTC
Aurora Cannabis acquired Internode Pharma Limited and HAP Pharma Limited to expand its distribution access to the UK medical cannabis market.
Source:Aug 19, 2026, 12:11 UTC
Aurora Cannabis confirms a hostile takeover bid for Curaleaf.
Source:Aug 11, 2026, 13:05 UTC
Curaleaf announced it will make a takeover offer for Aurora Cannabis, causing Aurora's stock to jump.
Aug 5, 2026, 14:57 UTC
Aurora Cannabis Inc. reported quarterly earnings of $0.04 per share for the quarter ended June 2026, beating the Zacks Consensus Estimate of a loss of $0.13 per share.
Source:Jul 23, 2026, 17:15 UTC
Safari Flower Company, a subsidiary of Aurora Cannabis Inc., received EU-GMP certification for its Niagara facility in Ontario, Canada.
Source:Jun 11, 2026, 13:05 UTC
Aurora Cannabis Inc. announced its financial and operational results for the fourth quarter and fiscal year 2026, reporting record annual global medical cannabis net revenue of $288.6 million and record annual adjusted EBITDA of $53.8 million.
Source:Jun 11, 2026, 13:05 UTC
Aurora Cannabis Inc. completed the accretive acquisition of Safari Flower Company in April 2026.
Source: